Scienmag

JULY 7, 2021

Researchers have produced vaccine-like immune responses to a dangerous bacterium by colonizing 26 healthy volunteers with a related, but harmless, commensal bacterial species.

Bacteria 75

Bacteria Bacterium Immune Response Vaccination 75

Pharmaceutical Technology

OCTOBER 6, 2022

Intended for intranasal administration, NGoXIM was demonstrated to be effective in animal models and elicited a durable and cross-protective immune response in proof-of-concept (PoC) studies. . A sexually transmitted disease, gonorrhoea is caused by the NG bacteria.

Vaccination 147

Vaccination Vaccine Development Bacterium 147

pharmaphorum

DECEMBER 4, 2020

This investigational multivalent protein subunit vaccine targets the outer surface protein A (OspA) of the bacterium Borrelia that causes the disease, an established mechanism of action for a Lyme disease vaccine. OspA is one of the most dominant surface proteins expressed by the bacteria when present in the ticks that spread the disease.

Vaccination 119

Vaccination Vaccine Bacterium Protein 119

XTalks

JULY 28, 2021

Merck has scored US Food and Drug Administration (FDA) approval for its next-generation pneumonia vaccine Vaxneuvance that covers 15 different strains of the pneumococcal bacteria that causes the infection. Both next-gen shots offer enhanced protection against bacteria that can cause pneumonia, blood infections and meningitis.

FDA Approval 68

FDA Approval Vaccination Vaccine Immune Response 68

pharmaphorum

JULY 14, 2021

Last year, Pfizer made almost $6 billion from its Prevnar 13 vaccine, which covers 13 common serotypes of Streptococcus pneumoniae – a bacteria which causes non-invasive illnesses like pneumonia, sinusitis and middle ear infections, as well as invasive diseases like meningitis. That is equivalent to 14% of Pfizer’s total revenues.

Immune Response 52

Immune Response Vaccination Vaccine Protein 52

XTalks

JANUARY 20, 2021

While diseases like celiac are associated with inappropriate activation of the immune system triggered by food antigens, this is not the case in IBS. In a normal, healthy intestine, foods do not trigger immune responses and so in a patient with IBS, something else must activate the response. Mouse and Human Studies.

Immune Response 52

Immune Response Research Allergies Protein 52

pharmaphorum

MAY 31, 2022

Last year, Affinivax reported positive phase 2 results with ASP3772, which targets 24 of the common serotypes of Streptococcus pneumoniae – a bacteria which causes non-invasive illnesses like pneumonia, sinusitis and middle ear infections, as well as invasive diseases like meningitis. GSK said it is paying $2.1

Vaccination 52

Vaccination Vaccine Bacterium Sales 52